Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
LadRx ( (LADX) ) just unveiled an announcement.
On December 11, 2024, LadRx Corporation announced its intention to seek marketing approval from the FDA for aldoxorubicin using existing clinical and supplemental non-clinical data under section 505(b)(2). However, the company acknowledged that it lacks the resources necessary to undertake the activities likely required to secure this approval.
Spark’s Take on LADX Stock
According to Spark, TipRanks’ AI Analyst, LADX is a Underperform.
LadRx faces significant financial hurdles, with ongoing losses and negative equity highlighting its financial difficulties. The technical indicators suggest a lack of positive momentum, while the negative P/E ratio reflects its unprofitability and lack of income appeal. These factors result in a low overall stock score, underscoring the potential risks for investors.
To see Spark’s full report on LADX stock, click here.
More about LadRx
Average Trading Volume: 1,003
Technical Sentiment Signal: Strong Sell
Current Market Cap: $821.9K
Find detailed analytics on LADX stock on TipRanks’ Stock Analysis page.